Evolus Target of Unusually Large Options Trading (EOLS)

Share on StockTwits

Evolus Inc (NASDAQ:EOLS) was the recipient of unusually large options trading activity on Thursday. Stock investors purchased 2,135 call options on the company. This represents an increase of 1,343% compared to the typical volume of 148 call options.

Institutional investors have recently added to or reduced their stakes in the business. Patriot Financial Group Insurance Agency LLC lifted its position in Evolus by 50.0% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the last quarter. Meeder Asset Management Inc. lifted its position in Evolus by 48.9% during the 1st quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock worth $39,000 after acquiring an additional 569 shares during the last quarter. Pearl River Capital LLC lifted its position in Evolus by 217.7% during the 1st quarter. Pearl River Capital LLC now owns 1,906 shares of the company’s stock worth $44,000 after acquiring an additional 1,306 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in Evolus by 8,877.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,975 shares of the company’s stock worth $45,000 after acquiring an additional 1,953 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY acquired a new position in Evolus during the 1st quarter worth $83,000. 19.33% of the stock is owned by hedge funds and other institutional investors.

Evolus stock traded down $1.97 on Friday, reaching $16.42. 54,681 shares of the stock were exchanged, compared to its average volume of 495,080. The firm has a market cap of $510.52 million, a price-to-earnings ratio of -10.47 and a beta of 5.01. The company has a debt-to-equity ratio of 0.96, a current ratio of 14.80 and a quick ratio of 14.52. Evolus has a twelve month low of $10.22 and a twelve month high of $39.50.

Evolus (NASDAQ:EOLS) last released its earnings results on Tuesday, April 30th. The company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.82) by ($0.11). As a group, sell-side analysts expect that Evolus will post -3.06 earnings per share for the current year.

A number of equities research analysts recently issued reports on EOLS shares. Stifel Nicolaus started coverage on shares of Evolus in a report on Monday, January 28th. They issued a “buy” rating and a $27.00 price objective for the company. Mizuho upped their price objective on shares of Evolus from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th. SunTrust Banks started coverage on shares of Evolus in a report on Wednesday, March 20th. They issued a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $35.00 price objective on shares of Evolus in a report on Tuesday, April 30th. Finally, HC Wainwright started coverage on shares of Evolus in a report on Thursday, February 14th. They issued a “buy” rating and a $37.00 price objective for the company. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $30.71.

TRADEMARK VIOLATION WARNING: This piece was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4344650/evolus-target-of-unusually-large-options-trading-eols.html.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Recommended Story: Municipal Bonds

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report